Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research Industry Presents United Front On Japan Reforms

Strong IP Waiver Opposition

Executive Summary

Three groups representing the domestic and multinational research-based pharma industry in Japan present a unified position as they call for policy changes they see as providing the right environment for investment, innovation and a sustainable healthcare system. 

You may also be interested in...



AbbVie Sees Solid Japan Outlook Despite 2020 Dip

AbbVie expects double-digit sales growth in Japan over the mid-term despite a decline last year, driven in large part by multi-indication plans for new products. 

Biden’s Vaccine Donation Plan Emphasizes American Production, Not IP Waivers

President announces ‘new effort’ to work with pharmaceutical companies, other nations to increase supply. Details remain in short supply, but Biden says plan will increase domestic production capacity to prepare ‘the next crises.’

Japan Approves First Coronavirus Vaccine But Hurdles Ahead?

Japanese authorities have issued their first approval for a coronavirus vaccine, to Pfizer/BioNTech’s mRNA product Comirnaty, but public vaccine hesitancy and logistics challenges could be hurdles to achieving high administration rates and effective herd immunity.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel